Potential Near-Term Catalysts
• CYP-001 – Phase 2 trial in respiratory distress
• CYP-001 – Phase 2 trial in aGvHD
• CYP-004 – Phase 3 trial in knee osteoarthritis
• CYP-002 – Restarting trials in critical limb ischemia
• TBD (MSC-seeded silicon dressing) – Phase 1/2 in diabetic foot ulcers
Valuation $2.95 on Risk-Adjusted NPV
We value Cynata Therapeutics at A$408m or A$2.95 per share on an undiluted basis, using a risk-adjusted net present
value (rNPV) method to discount future cash flows through to 2034, consistent with the expiry of current patent
families.
Sensitivities and Risks
Cynata Therapeutics is subject to all the risks typically associated with biotech company drug development,
including the possibility of unfavourable outcomes in clinical trials, regulatory decisions, success of competitors,
financing, and commercial decisions by partners or potential partners, including timing.
https://files.cynata.com/662/MST-Access---CYP-Initiation-Report---11Jun21-%28002%29.pdf
- Forums
- ASX - By Stock
- Ann: Quarterly Activity Report & Appendix 4C
Potential Near-Term Catalysts• CYP-001 – Phase 2 trial in...
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.72M |
Open | High | Low | Value | Volume |
20.0¢ | 21.0¢ | 20.0¢ | $4.156K | 20.74K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 54635 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 0.200 |
1 | 8187 | 0.195 |
2 | 31370 | 0.190 |
3 | 112017 | 0.185 |
1 | 10527 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 54635 | 3 |
0.215 | 102183 | 2 |
0.220 | 149010 | 5 |
0.225 | 20000 | 1 |
0.230 | 130470 | 1 |
Last trade - 15.43pm 26/04/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |